4 recruiting, 3 not yet recruiting, 2 completed, 1 terminated. 7 Phase 2, 3 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 2, Recruiting 2, Not yet recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 1 | 3 | Recruiting 2, Not yet recruiting 1 |
| Phase 3 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow Advanced Endometrial Cancer: new trials by email Literature Review of Advanced Endometrial Cancer trials Research Report on Advanced Endometrial Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer EG-007, Pembrolizumab 100 mg/ 4 ml (25 mg/ml) Injection, Lenvatinib Capsules - Advanced Endometrial Cancer | Phase 3 | Not yet recruiting | Evergreen Therapeutics, Inc. | 450 | 2026-12-01 | 2025-12-08 |
| Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem EG-007, Pembrolizumab 100 mg/4 mL (25 mg/ml) Injection, Lenvatinib Capsules - Advanced Endometrial Cancer | Phase 2 | Not yet recruiting | Evergreen Therapeutics, Inc. | 28 | 2026-08-01 | 2025-12-08 |
| A Phase 1 Study to Evaluate the Safety and Efficacy of OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer. OPB-201 - Endometrial Cancer Recurrent, Endometrial Cancer | Phase 1 | Not yet recruiting | Outpace Bio, Inc. | 30 | 2026-06-30 | 2026-06-24 |
| Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer fruquintinib, sintilimab, paclitaxel - Advanced Endometrial Cancer | Phase 3 | Recruiting | Hutchmed | 412 | 2024-12-12 | 2025-01-07 |
| A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha MOv18 IgE - Advanced Ovarian Cancer, Platinum-resistant Ovarian Cancer | Phase 1 | Recruiting | Epsilogen Ltd | 45 | 2024-09-03 | 2026-04-06 |
| A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor HB0025, Pemetrexed, Paclitaxel - Advanced NSCLC, Advanced Endometrial Cancer | Phase 1 / Phase 2 | Recruiting | Huabo Biopharm Co., Ltd. | 282 | 2024-01-31 | 2025-01-23 |
| GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer Pembrolizumab, Acasunlimab - Advanced Endometrial Cancer | Phase 2 | Withdrawn | Genmab | 2023-10-01 | 2024-04-30 | |
| Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus. TQB2450 injection, Anlotinib Hydrochloride Capsule, Carboplatin Injection - Advanced Endometrial Cancer, Sarcoma of Uterus | Phase 2 | Terminated | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 71 | 2022-08-26 | 2026-01-09 |
| Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer Envafolimab+Lenvatinib, Envafolimab - Advanced Endometrial Cancer | Phase 2 | Recruiting | 3D Medicines (Sichuan) Co., Ltd. | 108 | 2022-03-04 | 2026-03-25 |
| A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer TQB2450, Anlotinib - Advanced Endometrial Cancer | Phase 2 | Completed | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 170 | 2020-09-29 | 2025-05-28 |
| BKM120 as Second-line Therapy for Advanced Endometrial Cancer BKM120 - Advanced Endometrial Cancer | Phase 2 | Completed | Novartis Pharmaceuticals | 70 | 2011-02-01 | 2019-05-30 |
Endometrial Neoplasms (5) · Neoplasms (1) · Ovarian Neoplasms (1) · Triple Negative Breast Neoplasms (1)
Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Genital Diseases (5) · Genital Diseases, Female (5) · Genital Neoplasms, Female (5) · Neoplasms by Site (5) · Urogenital Diseases (5) · Urogenital Neoplasms (5) · Uterine Diseases (5) · Uterine Neoplasms (5) · Neoplasms (4) · Adnexal Diseases (1) · Breast Diseases (1) · Breast Neoplasms (1) · Endocrine Gland Neoplasms (1)
Paclitaxel (3) · pembrolizumab (3) · Carboplatin (2) · Doxorubicin (2) · Injections (2) · lenvatinib (2) · Docetaxel (1) · Gemcitabine (1) · HMPL-013 (1) · NVP-BKM120 (1) · Pemetrexed (1) · anlotinib (1) · envafolimab (1) · sintilimab (1)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (2) · Evergreen Therapeutics, Inc. (2) · 3D Medicines (Sichuan) Co., Ltd. (1) · Epsilogen Ltd (1) · Genmab (1) · Huabo Biopharm Co., Ltd. (1) · Hutchmed (1) · Novartis Pharmaceuticals (1) · Outpace Bio, Inc. (1)
China (5) · Belgium (2) · Italy (2) · Spain (2) · United States (2) · Australia (1) · Brazil (1) · Canada (1) · Denmark (1) · France (1) · Germany (1) · Japan (1) · Poland (1) · Russia (1) · Singapore (1)
Caicun Zhou, PhD. (1) · Jundong Li, PhD. (1) · Rebecca Kristeleit, MD (1) · Xiaohua Wu (1)